Jacob Trotter

Jacob Trotter

Auto-generated profile, based on publicly available information

Jacob Trotter

Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Advances in Radiation Oncology
Verified
Journal Article
Open access
JTJacob Trotter
Jacob Trotter
APAustin R. Pantel
Austin R. Pantel
BTBoon-Keng Kevin Teo
Boon-Keng Kevin Teo
FEFreddy E. Escorcia
Freddy E. Escorcia
TLTaoran Li
Taoran Li
NTNeil K. Taunk
Neil K. Taunk
Positron emission tomography (PET)/computed tomography (CT) has become a critical tool in clinical oncology with an expanding role in guiding radiation treatment planning. As its application and availability grows, it is increasingly important for practicing radiation oncologists to have a comprehensive understanding of how molecular imaging can be incorporated into radiation planning and recognize its potential limitations and pitfalls. The purpose of this article is to review the major approved positron-emitting radiopharmaceuticals clinically being used today along with the methods used for their integration into radiation therapy including methods of image registration, target delineation, and emerging PET-guided protocols such as biologically-guided radiation therapy and PET-adaptive therapy. A review approach was utilized using collective information from a broad review of the existing scientific literature sourced from PubMed search with relevant keywords and input from a multidisciplinary team of experts in medical physics, radiation treatment planning, nuclear medicine, and radiation therapy. A number of radiotracers imaging various targets and metabolic pathways of cancer are now commercially available. PET/CT data can be incorporated into radiation treatment planning through cognitive fusion, rigid registration, deformable registration, or PET/CT simulation techniques. PET imaging provides a number of benefits to radiation planning including improved identification and delineation of the radiation targets from normal tissue, potential automation of target delineation, reduction of intra- and inter-observer variability, and identification of tumor subvolumes at high risk for treatment failure which may benefit from dose intensification or adaptive protocols. However, PET/CT imaging has a number of technical and biologic limitations that must be understood when guiding radiation treatment. For PET guided radiation planning to be successful, collaboration between radiation oncologists, nuclear medicine physicians, and medical physics is essential, as well as the development and adherence to strict PET-radiation planning protocols. When performed properly, PET-based radiation planning can reduce treatment volumes, reduce treatment variability, improve patient and target selection, and potentially enhance the therapeutic ratio accessing precision medicine in radiation therapy.

1 March 2018 in Neurobiology of Learning and Memory
Verified
Journal Article
Closed access
Roxanne M MillerRoxanne M Miller
Roxanne M Miller
DMDavid Marriott
David Marriott
JTJacob Trotter
Jacob Trotter
THTyler Hammond
Tyler Hammond
DLDane Lyman
Dane Lyman
Jeffrey G. EdwardsJeffrey G. Edwards
Jeffrey G. Edwards

1 November 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PDF file
JTJ. Trotter
J. Trotter
JKJ.P. Kirkpatrick
J.P. Kirkpatrick
FMF. McSherry
F. McSherry
ARA. Rodrigues
A. Rodrigues
MDM.L. Dworkin
M.L. Dworkin
EHE.F. Hauck
E.F. Hauck